Clark Griffith, MD
Obstetrics & Gynecology · Dallas, TXNPI 1588666242
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,771 of the $3,084 with a category attached, or 89.8%. It is spread thinly across 34 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $745 and has fallen 57.1% since, to $320 in 2025.
Across 187 payments — averaging $16.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ascend Therapeutics US, LLC$366
- Astellas Pharma US Inc$289
- Fisher Scientific Company L.L.C.$258
- Exeltis, USA Inc.$241
- AbbVie$186
- Organon$181
- plus $2K from 28 others
Across 709 payments — averaging $1825.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sumitomo Pharma America, Inc.$804K
- AbbVie$406K
- Myovant Sciences GmbH$72K
- Myovant Sciences Inc.$13K
What the payments were for
- Consulting fees$150%
- Food & beverage$2,77190%
- Education$2588%
- Gifts$411%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ascend Therapeutics US, LLC | 61 | $366 |
| Astellas Pharma US Inc | 18 | $289 |
| Fisher Scientific Company L.L.C. | 1 | $258 |
| Exeltis, USA Inc. | 13 | $241 |
| AbbVie | 9 | $186 |
| Organon | 9 | $181 |
| Merck | 7 | $173 |
| Pfizer | 10 | $168 |
| Gynesonics, Inc. | 3 | $136 |
| Sumitomo Pharma America, Inc. | 7 | $111 |
| Mayne Pharma Commercial LLC | 5 | $109 |
| Bayer | 5 | $106 |
| Millicent US Inc | 4 | $98 |
| Amgen | 4 | $74 |
| Minerva Surgical, Inc | 2 | $69 |
| Vertical Pharmaceuticals, LLC | 3 | $62 |
| Aspira Women's Health Inc | 3 | $56 |
| Shield Therapeutics Inc | 2 | $44 |
| Integra Lifesciences Corporation | 2 | $35 |
| Channel Medsystems, Inc. | 1 | $33 |
| Therapeuticsmd, Inc. | 2 | $33 |
| Coopersurgical, Inc. | 2 | $31 |
| Exact Sciences | 2 | $30 |
| Johnson & Johnson | 2 | $28 |
| Innovation Technologies Inc | 1 | $24 |
| Myovant Sciences Inc. | 1 | $22 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Olympus America Inc. | 1 | $18 |
| Meditrina | 1 | $16 |
| Lupin Inc. | 1 | $14 |
| Avion Pharmaceuticals | 1 | $14 |
| Sage Therapeutics, LLC | 1 | $14 |
| Duchesnay USA Incorporated | 1 | $13 |
| Caldera Medical, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Procalcitonin$258
- ESTROGEL$121
- NEXPLANON$104
How this compares
$3,084 in reported general payments places this provider in the 75th percentile of 3,099 obstetrics & gynecology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 12 | $6,153 |
| Estradiol | 87 | $5,209 |
| Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet | 30 | $1,731 |
| Raloxifene Hcl | 28 | $1,252 |
| Estradiol (Twice Weekly)Estradiol | 15 | $1,226 |
| ValacyclovirValacyclovir Hcl | 24 | $1,106 |
| SynthroidLevothyroxine Sodium | 17 | $633 |
| Clobetasol Propionate | 19 | $385 |
| ProgesteroneProgesterone, Micronized | 13 | $312 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 13 | $153 |
| Levothyroxine Sodium | 38 | $116 |
| Fluconazole | 16 | $79 |
| Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid | 12 | $59 |
| Alprazolam | 17 | $25 |
| Fluoxetine Hcl | 20 | $25 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $289 | $6,15312 claims |
| AbbVieSynthroid | $186 | $63317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,099 obstetrics & gynecology providers in Texas.
Other obstetrics & gynecology in Dallas
- Dale StovallDallas$590K
- Quanita CrableDallas$176K
- Kamilia SmithDallas$119K
- Yolanda LawsonDallas$96K
- Patrick WeixDallas$96K
- David RogersDallas$44K
- Devin GarzaAustin$2M
- Shawn TassoneAustin$1.3M
- Karyn-Anne CumberbatchMissouri City$452K
- Robert AsgharianEl Paso$366K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.